Evidence map›Paper›PMID 32638225›Full record

ArticleMusculoskeletal surgery2022

Bone metastasis in extremity soft tissue sarcomas: risk factors and survival analysis using the SEER registry.

M H Younis, S Summers, J Pretell-Mazzini

Abstract read
PubMed Publisher
In one paragraph

Article in Musculoskeletal surgery, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Guideline
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

M H YounisMusculoskeletal Oncology Division, Department of Orthopaedics and Rehabilitation, University of Miami Miller School of Medicine, 1400 NW 12th Avenue, Fourth Floor, Room 4036, Miami, FL, 33136, USA.ORCID http://orcid.org/0000-0001-8810-6595
S SummersMusculoskeletal Oncology Division, Department of Orthopaedics and Rehabilitation, University of Miami Miller School of Medicine, 1400 NW 12th Avenue, Fourth Floor, Room 4036, Miami, FL, 33136, USA.ORCID http://orcid.org/0000-0003-4964-0992
J Pretell-MazziniMusculoskeletal Oncology Division, Department of Orthopaedics and Rehabilitation, University of Miami Miller School of Medicine, 1400 NW 12th Avenue, Fourth Floor, Room 4036, Miami, FL, 33136, USA. J.pretell@med.miami.edu.ORCID http://orcid.org/0000-0001-5024-1206
University of Miami · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionWhile lung is the most common site of metastasis, bone metastasis of soft tissue sarcoma is a part of the natural history affecting the prognosis of these patients. To date, no studies have analyzed the histologic subtypes more likely to metastasize to bone, the risk factors for bone metastasis at initial presentation, or the effect that bone metastasis has on the survival of these patients. MATERIAL/

methodsPatients were identified from the Surveillance, Epidemiology and End Results database with primary extremity STS between 2010 and 2015. Risk factors for early bone metastasis, survival based on different sites of metastasis, and prognostic factors of survival were analyzed.

resultsAmong 8,234 STS, 2.2% (n = 180) presented with skeletal metastasis. Bone metastasis was more likely when regional lymph nodes were involved (OR = 4.48, p = 0.008). Deep and moderate or high-grade sarcomas had 5-12-fold tendency to present with bone and lung metastasis (p = 0.046, 0.006, 0.030, respectively). The 5-year survival rate was 41.2% (26.9-54.9%) for isolated bone metastasis and 32.9% (21.2-45.1%) for patients with bone and lung metastasis. Resection of the primary sarcoma was the only significant predictor of survival (HR = 0.44, p = 0.021) for patients with bone metastasis.

conclusionHigh tumor grade, deep location to fascia and regional lymph node metastasis are significant risk factors for skeletal metastasis at diagnosis of an extremity STS. While neither systemic chemotherapy nor radiotherapy of the primary sarcoma has a significant influence on survival in the presence of bone metastasis, radical resection of the primary STS is associated with increased survival.

Indexed as

SarcomaSoft Tissue NeoplasmsExtremitiesHumansPrognosisRegistriesRetrospective StudiesRisk FactorsSurvival AnalysisBone metastasisRisk factorsSoft tissue sarcomaSurvival

Identifiers

PMID32638225
OpenAlexW3041140794

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.